Wednesday, 26 October 2016

Acute Ischemic Stroke Market Consumption 2016 Forecast to 2022

The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
- The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects
- The report assesses Acute Ischemic Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Acute Ischemic Stroke Overview 9
Therapeutics Development 10
Pipeline Products for Acute Ischemic Stroke - Overview 10
Acute Ischemic Stroke - Therapeutics under Development by Companies 11
Acute Ischemic Stroke - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Acute Ischemic Stroke - Products under Development by Companies 16
Acute Ischemic Stroke - Companies Involved in Therapeutics Development 18
AB Science SA 18
AstraZeneca Plc 19
Biogen Inc 20
D-Pharm Ltd. 21
Daiichi Sankyo Company, Limited 22
DiaMedica Inc. 23
Digna Biotech, S.L. 24
Glucox Biotech AB 25
Jeil Pharmaceutical Co., Ltd. 26
Lumosa Therapeutics Co., Ltd. 27
Mitsubishi Tanabe Pharma Corporation 28
Pharmicell Co., Ltd. 29
PhytoHealth Corporation 30
Remedy Pharmaceuticals, Inc. 31
Saneron CCEL Therapeutics, Inc. 32
Simcere Pharmaceutical Group 33
Stemedica Cell Technologies, Inc. 34
Acute Ischemic Stroke - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 39
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
3K3A-APC - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
AB-022 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ApTLR-4FT - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Cellgram-IS - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
DB-017 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
DM-199 - Drug Profile 52

Contact Info:
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)                                                   

Get in touch:

No comments:

Post a Comment